Isocitrate Dehydrogenase Inhibitors in Cancer Chemotherapy

Isocitrate Dehydrogenase Inhibitors in Cancer Chemotherapy

1st Edition - September 1, 2022

Write a review

  • Editor: Robert Musiol
  • Hardcover ISBN: 9780323901970

Purchase options

Purchase options
Available for Pre-Order
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Isocitrate Dehydrogenase Inhibitors in Cancer Chemotherapy presents an in-depth and up-to-date compilation of research on isocitrate dehydrogenase as drug target to be used as a sensitizing agent in chemotherapy. The book brings a combination of medicinal, biological and chemical points-of-view to fully cover the subject. It discusses topics such as IDH place in cellular metabolism, mutant IDH as drug target, mono- and poli-therapies based on IDH1/2 inhibitors, and IDH1/2 inhibitors in leukemia, gliomas and other brain tumors, and potential importance in gastrointestinal cancers. Additionally, it discusses isocitrate dehydrogenases as target for theranostics, therapeutic strategies and future perspectives.This is a valuable resource for cancer researchers, oncologists and members of the biomedical field who are interested to learn more about IDH inhibitors and their potential as sensitizing agents for chemotherapy.

Key Features

  • Presents comprehensive and up-to-date review of current trends in design IDH inhibitors and their use as adjuvant therapy
  • Contains summarized tables and schematic diagrams in each chapter to give a clear overview of the recent findings in a didactic manner
  • Brings not only relevant information of current research but also new ideas and suggestions for further investigations to help advance the field

Readership

Cancer researchers, medical scientists, clinicians, graduate students, pharmacologists

Table of Contents

  • 1. Isocitrate dehydrogenase and its place in cellular metabolism
    2. Wild type and mutant IDH as drug target
    3. Holy grail of combination therapy? Possibilities and limitations of mono- and poli-therapies based on IDH1/2 inhibitors
    4. Two faced IDH. The good and bad in prognosis
    5. Inhibitors of IDH1/2 in leukemias
    6. Inhibitors of IDH1/2 in gliomas and other brain tumors
    7. Potential importance of IDH in gastrointestinal cancers
    8. Isocitrate dehydrogenases as target for theranostics
    9. Resistance emerging and therapeutic strategies
    10. Challenges and future perspectives

Product details

  • No. of pages: 200
  • Language: English
  • Copyright: © Academic Press 2022
  • Published: September 1, 2022
  • Imprint: Academic Press
  • Hardcover ISBN: 9780323901970

About the Editor

Robert Musiol

Prof. Dr Robert Musiol received a PhD in organic chemistry in 2005 and habilitation in pharmacy in 2013. For roughly twenty years he is connected with University of Silesia in Katowice, Poland, where he teaches medicinal chemistry, pharmacology and toxicology. His scientific interest is focused on drug design and particularly polypharmacological design of potential anticancer drugs. Recently he is involved in redesign of IDH1 inhibitors towards multi-kinase activity. He is a co-author of more than one hundred scientific papers and thirty patents. Being involved in teaching and popularizing science, he was supervisor of four doctorates and more than forty master’s degree students.

Affiliations and Expertise

Professor, University of Silesia in Katowice, Poland

Ratings and Reviews

Write a review

There are currently no reviews for "Isocitrate Dehydrogenase Inhibitors in Cancer Chemotherapy"